Navigation Links
Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
Date:10/14/2008

Former Director of the Office of National Drug Control Policy to Moderate

First Educational Webinar: When Good Medicines Become Bad Drugs

FRAZER, Pa., Oct. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it is embarking on a national educational program designed to promote greater awareness among patients, caregivers and the public about the importance of appropriate and responsible use of prescription opioid medications. The initiative, When Good Medicines Become Bad Drugs(SM), will include a series of free educational programs on timely topics. The first webcast, moderated by General Barry R. McCaffrey, former Director of the Office of National Drug Control Policy, will take place on Tuesday, October 21, 2008, from 3:00 p.m. - 4:00 p.m. Eastern, and will focus on safeguarding medications in the home.

"This program is consistent with Cephalon's commitment to ensure that prescription medications are used safely by the appropriate patients," said Dr. Lesley Russell, Executive Vice President and Chief Medical Officer at Cephalon. "Currently, 71 percent of people who abuse prescription pain medicines received them from a friend or family member, not through a doctor's prescription. The aim of this program is to heighten patient and public awareness of, and responsibility for, safeguarding the use of these important medications."

About When Good Medicines Become Bad Drugs Webcast

This free webcast will provide practical tips about what patients, caregivers and the public can do to safeguard medications and help prevent abuse and diversion of prescription opioids. The webcast will take place on October 21, 2008, from 3:00 p.m. - 4:00 p.m. Eastern. Participants can register at http://video.webcasts.com/events/vxmd001/28151/.

Panelists will include:

Moderator: General Barry R. McCaffrey, former Director of the Off
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Va., April 10 Insmed Inc. (Nasdaq:,INSM), a ... of a letter and questionnaire from the Chairman ... Subcommittee on Health,on the possible development of legislation ... Sent to approximately 30 stakeholders in the biotechnology ...
... ATS 3f Valve, MINNEAPOLIS, April 10 ... marketer of state-of-the-art cardiac,surgery products and services, today ... ATS 3f(R) Aortic Bioprosthesis. Canadian,regulatory approval was received ... was performed by Benoit de Varennes, MD, MSc, ...
... Vision of Becoming a Global Leader in ... ... Mass., April 10 ,Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and ... entered,into a definitive agreement pursuant to which Takeda will acquire,Millennium for ...
Cached Biology Technology:Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 2Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway 3ATS Medical Announces First North American Commercial Implant of the ATS 3f Aortic Bioprosthesis 2ATS Medical Announces First North American Commercial Implant of the ATS 3f Aortic Bioprosthesis 3Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 2Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 3Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 4Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 5Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 6Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 7
(Date:4/17/2014)... Kansas State University engineer has developed a patented ... improvised explosive devices. The same technique could help ... Steven M. and Kay L. Theede chair in ... engineering, and his research team have created a ... in car trunks. The distance detection method ...
(Date:4/17/2014)... RIVERSIDE, Calif. One day about eight years ago, ... of California, Riverside, and her father were on a field ... stumbled upon an orchid they had never seen before. , ... authority on orchids. The orchid turned out to be ... Silveras: Lophiaris silverarum . , "Lophiaris" is the genus ...
(Date:4/17/2014)... release is available in German . ... pay the protection money demanded of him, he can expect ... required, however, as fear of the consequences is enough to ... in parasitic birds, which lay their eggs in other birds, ... the brood parasites take their revenge by destroying the entire ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... too much growth in patients has now also been ... can lead to very different conditions, according to research ... IMAGe* syndrome is a rare developmental disorder which ... body and organ size. Without treatment, the disorder can ...
... climate change because they don,t understand the science behind ... more proficient in technical reasoning, would public consensus match ... the journal Nature Climate Change suggests that ... members of the public become more science literate and ...
... see how a common house sparrow and a Tyrannosaurus Rex might ... weighs less than an ounce, and the other is a dinosaur ... scales at more than eight tons. For all their ... than many believed. A new study, led by Harvard scientists, has ...
Cached Biology News:Variations of a single gene can lead to too much or too little growth, study shows 2Yale study concludes public apathy over climate change unrelated to science literacy 2Timing is everything 2Timing is everything 3Timing is everything 4
The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
... genetically engineered endonuclease. This unique enzyme degrades ... having no proteolytic activity. It is effective ... possesses an exceptionally high specific activity. Ideal ... proteins, its use enables compliance with FDA ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Rice microRNA Microarray contains ...
... selects single cells, or clusters, with rapid, ... all, a single cell can be targeted, ... collected into the pipette, and automatically transferred ... plate. Quixells unique aspiration and expulsion system ...
Biology Products: